HK1124619A1 - Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk alk - Google Patents

Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk alk

Info

Publication number
HK1124619A1
HK1124619A1 HK09101197.0A HK09101197A HK1124619A1 HK 1124619 A1 HK1124619 A1 HK 1124619A1 HK 09101197 A HK09101197 A HK 09101197A HK 1124619 A1 HK1124619 A1 HK 1124619A1
Authority
HK
Hong Kong
Prior art keywords
alk
tyrosine kinase
extracellular domain
receptor tyrosine
antibodies binding
Prior art date
Application number
HK09101197.0A
Other languages
English (en)
Chinese (zh)
Inventor
Der Maur Adrian Auf
Peter Lichtlen
Alcide Barberis
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Publication of HK1124619A1 publication Critical patent/HK1124619A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09101197.0A 2006-04-28 2009-02-10 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk alk HK1124619A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Publications (1)

Publication Number Publication Date
HK1124619A1 true HK1124619A1 (en) 2009-07-17

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101197.0A HK1124619A1 (en) 2006-04-28 2009-02-10 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk alk

Country Status (17)

Country Link
US (3) US7902340B2 (es)
EP (2) EP2604627A1 (es)
JP (2) JP5431920B2 (es)
KR (1) KR101457228B1 (es)
CN (1) CN101443361B (es)
AU (1) AU2007246144B2 (es)
BR (1) BRPI0710971A2 (es)
CA (1) CA2650822C (es)
DK (1) DK2013236T3 (es)
ES (1) ES2547248T3 (es)
HK (1) HK1124619A1 (es)
IL (1) IL194752A0 (es)
MX (1) MX2008013705A (es)
NZ (1) NZ572248A (es)
PL (1) PL2013236T3 (es)
RU (1) RU2460540C2 (es)
WO (1) WO2007124610A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604627A1 (en) * 2006-04-28 2013-06-19 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
PT3444274T (pt) 2008-06-25 2021-03-17 Novartis Ag Anticorpos que inibem tnf estáveis e solúveis
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
WO2017066136A2 (en) 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
CN115925973A (zh) 2015-10-23 2023-04-07 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
SG10201913655UA (en) 2017-04-26 2020-03-30 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
EP3749682A4 (en) * 2018-02-09 2021-11-17 Acceleron Pharma Inc. METHOD OF TREATMENT OF HETEROTOPIC OSSIFICATION
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
CA2412650C (en) * 2000-06-14 2011-08-02 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
CN102093477B (zh) * 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
EP1789552A2 (en) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP2604627A1 (en) * 2006-04-28 2013-06-19 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK

Also Published As

Publication number Publication date
US9512411B2 (en) 2016-12-06
CA2650822C (en) 2017-03-14
EP2013236A1 (en) 2009-01-14
NZ572248A (en) 2011-08-26
RU2008146922A (ru) 2010-06-10
KR101457228B1 (ko) 2014-11-04
CA2650822A1 (en) 2007-11-08
RU2460540C2 (ru) 2012-09-10
JP5431920B2 (ja) 2014-03-05
MX2008013705A (es) 2008-11-06
US8945563B2 (en) 2015-02-03
DK2013236T3 (en) 2015-09-21
EP2013236B1 (en) 2015-06-17
US20150203829A1 (en) 2015-07-23
CN101443361A (zh) 2009-05-27
CN101443361B (zh) 2015-08-19
PL2013236T3 (pl) 2015-12-31
AU2007246144A1 (en) 2007-11-08
US7902340B2 (en) 2011-03-08
WO2007124610A1 (en) 2007-11-08
ES2547248T3 (es) 2015-10-02
US20080118512A1 (en) 2008-05-22
AU2007246144B2 (en) 2012-12-06
IL194752A0 (en) 2011-08-01
KR20080113261A (ko) 2008-12-29
JP2013226144A (ja) 2013-11-07
JP2009535021A (ja) 2009-10-01
EP2604627A1 (en) 2013-06-19
US20110159008A1 (en) 2011-06-30
BRPI0710971A2 (pt) 2011-05-31
JP5911821B2 (ja) 2016-04-27

Similar Documents

Publication Publication Date Title
IL194752A0 (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
HRP20191341T8 (hr) Protutijela koja vežu ljudski cgrp receptor
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
IL245876A (en) A method for making binding molecules that bind to a human ox40r receptor
IL212589A0 (en) Binding proteins inhibiting the vegf-a receptor interaction
PT1981902E (pt) Antagonistas dos recetores nogo
EP2350024A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
IL217155A0 (en) Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
PL2121758T3 (pl) Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści
ZA200903499B (en) Indoles which act as via receptor antagonists
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
EP2313517A4 (en) TYROSINE KINASE RECEPTOR ASSAYS
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists
SI2137184T1 (sl) IMIDAZO(1,2-a)PIRIDINSKE SPOJINE KOT INHIBITORJI RECEPTORSKE TIROZINSKE KINAZE
AU2010904903A0 (en) Antibodies directed to the receptor tyrosine kinase c-Met

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200427